Cullinan Therapeutics, Inc.
CGEM
$8.71
$0.202.35%
| Weiss Ratings | CGEM - NASDAQ | Click to Compare |
Click to Compare |
Click to Compare |
| Rating | ||||
| Reward Index | Very Weak | |||
| Risk Index | Weak | |||
| Risk Grade | D | |||
| Reward Grade | E | |||
| Rating Factors | CGEM - NASDAQ | Click to Compare |
Click to Compare |
Click to Compare |
| Dividend Index | -- | |||
| Growth Index | Weak | |||
| Efficiency Index | Very Weak | |||
| Solvency Index | Excellent | |||
| Total Return Index | Weak | |||
| Volatility Index | Weak | |||
| Beta / Standard Deviation | CGEM - NASDAQ | Click to Compare |
Click to Compare |
Click to Compare |
| Beta | 1.03 | |||
| Price History | CGEM - NASDAQ | Click to Compare |
Click to Compare |
Click to Compare |
| 7-Day Total Return | 3.08% | |||
| 30-Day Total Return | -17.52% | |||
| 60-Day Total Return | -33.31% | |||
| 90-Day Total Return | -45.08% | |||
| Year to Date Total Return | -29.70% | |||
| 1-Year Total Return | -46.73% | |||
| 2-Year Total Return | -21.53% | |||
| 3-Year Total Return | -34.36% | |||
| 5-Year Total Return | -- | |||
| 52-Week High % Change | -71.81% | |||
| 52-Week Low % Change | 7.72% | |||
| Price | CGEM - NASDAQ | Click to Compare |
Click to Compare |
Click to Compare |
| 52-Week High Price | $30.19 | |||
| 52-Week Low Price | $7.90 | |||
| 52-Week Low Price (Date) | Mar 04, 2025 | |||
| 52-Week High Price (Date) | May 07, 2024 | |||
| Valuation | CGEM - NASDAQ | Click to Compare |
Click to Compare |
Click to Compare |
| Market Cap | 497.94M | |||
| Enterprise Value | 101.12M | |||
| Price/Earnings (TTM) | -- | |||
| Earnings Per Share (TTM) | -3.14 | |||
| Earnings Per Share Growth | -15.34% | |||
| Price/Earnings To Growth | -- | |||
| Price/Sales (TTM) | -- | |||
| Price/Book (Q) | 0.84 | |||
| Enterprise Value/Revenue (TTM) | -- | |||
| Price | $8.71 | |||
| Enterprise Value/EBITDA (TTM) | -0.51 | |||
| Enterprise Value/EBIT | -0.51 | |||
| Market Cap Category | Small Cap | |||
| Dividends and Shares | CGEM - NASDAQ | Click to Compare |
Click to Compare |
Click to Compare |
| Shares Outstanding | 58.58M | |||
| Dividend Yield | -- | |||
| Div. Per Share (Most Recent) | -- | |||
| Dividend Per Share (TTM) | -- | |||
| Payout Ratio (TTM) | -- | |||
| Dividend Per Share (Most Recent) | -- | |||
| Company Info | CGEM - NASDAQ | Click to Compare |
Click to Compare |
Click to Compare |
| Phone Number | 617 410 4650 | |||
| Address | One Main Street Cambridge, MA 02142 | |||
| Website | cullinantherapeutics.com | |||
| Country | United States | |||
| Year Founded | 2016 | |||
| Profitability | CGEM - NASDAQ | Click to Compare |
Click to Compare |
Click to Compare |
| Operating Margin (TTM) | -- | |||
| Profit Margin | -- | |||
| Management Effectiveness | CGEM - NASDAQ | Click to Compare |
Click to Compare |
Click to Compare |
| Return on Assets | -22.26% | |||
| Return on Equity | -- | |||
| Income Statement | CGEM - NASDAQ | Click to Compare |
Click to Compare |
Click to Compare |
| Revenue (TTM) | -- | |||
| Total Revenue (TTM) | -- | |||
| Revenue Per Share | -- | |||
| Gross Profit (TTM) | -- | |||
| EBITDA (TTM) | -196.61M | |||
| EBIT (TTM) | -196.92M | |||
| Net Income (TTM) | -167.38M | |||
| Net Income Avl. to Common (TTM) | -167.38M | |||
| Total Revenue Growth (Q YOY) | -- | |||
| Earnings Growth (Q YOY) | -86.39% | |||
| EPS Diluted (TTM) | -3.14 | |||
| EPS Diluted Growth (Q YOY) | -46.24% | |||
| Balance Sheet | CGEM - NASDAQ | Click to Compare |
Click to Compare |
Click to Compare |
| Cash and Short-Term Inv. (Q) | 398.98M | |||
| Cash Per Share (Q) | $6.81 | |||
| Total Current Assets (Q) | 414.67M | |||
| Total Preferred Equity (Q) | -- | |||
| Total Equity (Q) | 590.33M | |||
| Current Ratio (Q) | 13.530 | |||
| Book Value Per Share (Q) | $10.09 | |||
| Total Assets (Q) | 621.82M | |||
| Total Current Liabilities (Q) | 30.65M | |||
| Total Debt (Q) | 2.15M | |||
| Total Liabilities (Q) | 31.50M | |||
| Total Common Equity (Q) | 590.33M | |||
| Cash Flow | CGEM - NASDAQ | Click to Compare |
Click to Compare |
Click to Compare |
| Cash from Investing (TTM) | -136.31M | |||
| Cash from Financing (TTM) | 266.19M | |||
| Net Change in Cash (TTM) | -15.43M | |||
| Levered Free Cash Flow (TTM) | -84.86M | |||
| Cash from Operations (TTM) | -145.30M | |||
